Not applicableStudy completedNCT04737928
What this trial is testing
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
Who this might be right for
Glaucoma, Primary Open Angle
Santen Pharmaceutical (Taiwan) Co., LTD 1